Filing Flows › Cartesian Therapeutics (RNAC) › Recalls, complaints & regulation

Cartesian Therapeutics (RNAC): clinical trials

Cartesian Therapeutics (RNAC) beyond its filings: 5 active clinical trials.

Cartesian Therapeutics' latest quarter

Cartesian Therapeutics, Q1 2026: revenue $78K (-93% year over year), net loss $39.2M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Cartesian Therapeutics have?

5 active studies on ClinicalTrials.gov, 1 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.